FCX vs LAB · P/E 38, rev $25.45B vs rev $174.4M
Freeport-McMoran Copper & Gold Inc (FCX) versus Standard Biotools Inc (LAB) — a side-by-side from cached financials, not a winner call.
Freeport-McMoran Copper & Gold Inc (FCX) is a copper company listed on US.
Standard Biotools Inc (LAB) is a medical devices company listed on NASDAQ.
Latest reported FCX revenue for 2024-12-31 was $25.45B. Net income was $4.40B. Revenue was up 11.4% from 2023-12-31 to 2024-12-31. FCX currently screens at market cap $67.80B and trailing P/E 38.0.
Latest reported LAB revenue for 2024-12-31 was $174.4M. Net income was -$138.9M. Revenue was up 64.0% from 2023-12-31 to 2024-12-31. LAB currently screens at market cap $317.1M.
FCX currently screens at market cap $67.80B and trailing P/E 38.0. LAB currently screens at market cap $317.1M.
Not investment advice. Open the FCX and LAB stock pages for the full models.
Not investment advice.